Healthcare Industry News: ImmunoGen
News Release - March 21, 2011
Selventa Names John Tagliamonte as Senior Vice President of Corporate DevelopmentSeasoned Life Science Business Executive Brings Significant Pharmaceutical and Diagnostic Experience
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)-- Selventa™ announced today that John Tagliamonte has been appointed Senior Vice President of Corporate Development effective immediately. Mr. Tagliamonte brings over 20 years of pharmaceutical and diagnostic experience to the Selventa team. Mr. Tagliamonte’s new role includes promoting and establishing strategic partnerships with global pharmaceutical and biotechnology companies to optimize portfolio development through early patient stratification.
“John is an accomplished executive who has tremendous experience in business development. His expertise in the diagnostic and therapeutic space as well as his knowledge of biotechnology and large pharmaceutical industries will help us provide our partners with the best collaborative deal structures,” said David de Graaf, President and CEO of Selventa. “His credibility and exceptional customer relations will be instrumental in strategically driving our vision of Personalized Healthcare.”
Selventa leverages patient data and innovative analytics to find optimal treatments for the right patients. Ultimately, the value includes portfolio optimization through evidence-driven identification and validation of mechanisms for patient stratification and combination therapies, which maximize broad response or desired efficacy.
“I am excited about this opportunity to work with creative and innovative team members at Selventa,” said Mr. Tagliamonte. “The company is currently addressing key R&D challenges in the pharmaceutical industry. The vision of stratifying patients early in the R&D process to optimize the development of portfolios poised for clinical success will undoubtedly alter pharmaceutical industry’s productivity levels. In my role, I will carefully listen to our clients’ key pain points and match their needs through our strategic partnership business model.”
Before joining Selventa, Mr. Tagliamonte was VP, Business Development at Anchor Therapeutics where he led a transformative partnership with Johnson & Johnson that enabled the company's Series B financing. Prior to Anchor Therapeutics, he led strategy and corporate development with ImmunoGen to advance the company's targeted anti-cancer therapeutics candidates through the clinical programs as well as evaluated and optimized Intellectual Property estates. He previously held senior strategic corporate development roles at Millipore, Laureate Pharma and Johnson & Johnson, and managed dozens of partnerships collectively valued over $1B. He earned his BS from Tufts University and his MBA from Boston College.
Founded in 2002 and privately-held, Selventa helps clients find optimal treatments for the right patients by offering scientific consulting services, licensed software products and strategic partnerships. The company analyzes molecular patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics. Selventa engages in short-, mid- and long-term relationships with top-tier pharmaceutical and life science companies to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases, inflammation and drug safety. For more information, visit www.selventa.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.